AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more
AC Immune Ltd (ACIU) - Net Assets
Latest net assets as of September 2025: $62.44 Million USD
Based on the latest financial reports, AC Immune Ltd (ACIU) has net assets worth $62.44 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($171.61 Million) and total liabilities ($109.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $62.44 Million |
| % of Total Assets | 36.39% |
| Annual Growth Rate | 33.03% |
| 5-Year Change | -47.9% |
| 10-Year Change | 58.03% |
| Growth Volatility | 121.17 |
AC Immune Ltd - Net Assets Trend (2013–2024)
This chart illustrates how AC Immune Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AC Immune Ltd (2013–2024)
The table below shows the annual net assets of AC Immune Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $112.27 Million | -30.11% |
| 2023-12-31 | $160.64 Million | -4.94% |
| 2022-12-31 | $168.99 Million | -27.15% |
| 2021-12-31 | $231.98 Million | +7.66% |
| 2020-12-31 | $215.48 Million | -20.91% |
| 2019-12-31 | $272.44 Million | +53.38% |
| 2018-12-31 | $177.62 Million | +52.02% |
| 2017-12-31 | $116.84 Million | -17.94% |
| 2016-12-31 | $142.38 Million | +100.41% |
| 2015-12-31 | $71.04 Million | +202.74% |
| 2014-12-31 | $23.47 Million | +382.86% |
| 2013-12-31 | $4.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AC Immune Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29814700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.23 Million | 1.98% |
| Other Comprehensive Income | $-5.00K | 0.00% |
| Other Components | $478.29 Million | 426.02% |
| Total Equity | $112.27 Million | 100.00% |
AC Immune Ltd Competitors by Market Cap
The table below lists competitors of AC Immune Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
7707
TWO:7707
|
$133.06 Million |
|
SKYX Platforms Corp
NASDAQ:SKYX
|
$133.08 Million |
|
Morepen Laboratories Limited
NSE:MOREPENLAB
|
$133.08 Million |
|
Pollard Banknote Limited
PINK:PBKOF
|
$133.10 Million |
|
Nex Point Public Company Limited
BK:NEX
|
$132.97 Million |
|
Grand Fortune Securities Co Ltd
TWO:6026
|
$132.94 Million |
|
Duopharma Biotech Bhd
KLSE:7148
|
$132.90 Million |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
$132.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AC Immune Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 160,643,000 to 112,270,000, a change of -48,373,000 (-30.1%).
- Net loss of 50,916,000 reduced equity.
- New share issuances of 111,000 increased equity.
- Other comprehensive income increased equity by 46,000.
- Other factors increased equity by 2,386,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.92 Million | -45.35% |
| Share Issuances | $111.00K | +0.1% |
| Other Comprehensive Income | $46.00K | +0.04% |
| Other Changes | $2.39 Million | +2.13% |
| Total Change | $- | -30.11% |
Book Value vs Market Value Analysis
This analysis compares AC Immune Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.95x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 34.28x to 2.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.10 | $3.32 | x |
| 2014-12-31 | $0.42 | $3.32 | x |
| 2015-12-31 | $1.28 | $3.32 | x |
| 2016-12-31 | $2.84 | $3.32 | x |
| 2017-12-31 | $2.04 | $3.32 | x |
| 2018-12-31 | $2.87 | $3.32 | x |
| 2019-12-31 | $3.83 | $3.32 | x |
| 2020-12-31 | $3.00 | $3.32 | x |
| 2021-12-31 | $3.10 | $3.32 | x |
| 2022-12-31 | $2.02 | $3.32 | x |
| 2023-12-31 | $1.90 | $3.32 | x |
| 2024-12-31 | $1.13 | $3.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AC Immune Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -186.44%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 2.06x
- Recent ROE (-45.35%) is below the historical average (-36.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -286.01% | -130.17% | 0.68x | 3.24x | $-11.64 Million |
| 2014 | 45.78% | 35.50% | 1.00x | 1.29x | $8.40 Million |
| 2015 | 28.53% | 51.85% | 0.49x | 1.13x | $13.17 Million |
| 2016 | -4.98% | -30.57% | 0.15x | 1.10x | $-21.33 Million |
| 2017 | -22.60% | -130.39% | 0.15x | 1.13x | $-38.09 Million |
| 2018 | -28.68% | -708.24% | 0.04x | 1.11x | $-68.71 Million |
| 2019 | 16.68% | 41.14% | 0.37x | 1.10x | $18.20 Million |
| 2020 | -28.74% | -401.28% | 0.06x | 1.11x | $-83.47 Million |
| 2021 | -31.47% | -7732.63% | 0.00x | 1.13x | $-96.19 Million |
| 2022 | -41.87% | -1798.04% | 0.02x | 1.10x | $-87.65 Million |
| 2023 | -33.76% | -366.41% | 0.08x | 1.14x | $-70.30 Million |
| 2024 | -45.35% | -186.44% | 0.12x | 2.06x | $-62.14 Million |
Industry Comparison
This section compares AC Immune Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AC Immune Ltd (ACIU) | $62.44 Million | -286.01% | 1.75x | $133.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |